Iran participation in a large randomized clinical trauma trial in the world : Crash-2

Objective : inform readers and to illustrate Methods: This randomized controlled trial was undertaken in 274 hospitals in 40 countries. Iran was one of the countries which participated in this great trial. This trial was conducted in Imam Hosein, Erfan, Namazi, Loqman,Fayaz Bakhsh Hospitals. Results: 10 096 patients were allocated to tranexamic acid and 10 115 to placebo, of whom 10 060 and 10 067, respectively, were analyzed. All-cause mortality was significantly reduced with tranexamic acid (1463 [14·5%] tranexamic acid group vs. 1613 [16·0%] placebo group; relative risk 0·91, 95% CI 0·85–0·97; p=0·0035). The risk of death due to bleeding was significantly reduced (489 [4·9%] vs. 574 [5·7%]; relative risk 0·85, 95% CI 0·76–0·96; p=0·0077). Conclusion: Tranexamic acid safely reduced the risk of death in bleeding trauma patients in this study. On the basis of these results, tranexamic acid should be considered for use in bleeding trauma patients. The researchers estimate that administering TXA soon after injury could prevent up to 100,000 deaths per year across the world. “In Iran this treatment could prevent 881 deaths each year.